Welcome to my Blog.... Mesothelioma

Abdominal Mesothelioma, Mesothelioma, Mesothelioma diagnosis, Mesothelioma Lawyer

==============================================================================

Saturday, June 21, 2008

Fwd: Molecular evidence for a clonal relationship between multiple lesions in patients with unknown primary adenocarcinoma.



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Molecular evidence for a clonal relationship between multiple lesions in patients with unknown primary adenocarcinoma.
To: mesothelioma77@gmail.com


[1]Int J Cancer. 2008 Jun 17;
Speel EJ, van de Wouw AJ, Claessen SM, Haesevoets A, Hopman AH, van der Wurff AA, Osieka R, Buettner R, Hillen HF, Ramaekers FC

Unknown primary adenocarcinoma (UPA) comprises a group of heterogeneous cancers of great clinical and biological interest. UPA presents as metastatic disease without a detectable primary site after medical workup. Here we investigated whether or not a clonal relationship exists between multiple tumors within individual UPA patients. A molecular resemblance would argue for an early clonal outgrowth of tumor cells from the primary lesion, a mutual feature observed within this group of neoplasms. In 14 patients with UPA multiple tumors, obtained at autopsy, were analyzed by molecular allelotyping and immunohistochemistry. In addition, tumors of 4 patients could be analyzed by comparative genomic hybridization (CGH). Similar genetic and phenotypic profiles were used as indicator for a clonal relationship, whereas different profiles implicate independent tumors. The molecular data indicated that the multiple lesions in the 14 UPA patients, including the primary tumors, are clonally related. In agreement with the theory of tumor progression, some metastatic lesions showed additional genetic alterations besides the characteristics that were shared with the primary tumor. Furthermore, 8 UPA patients had tumors with a high frequency of allelic loss and/or imbalance (FALI; 43-71%), while 6 patients demonstrated a lower FALI (14-29%), suggesting the occurrence of chromosomal instability in the former group. Our data provide molecular evidence for a clonal relationship between multiple metastases and the primary tumor within individual UPA patients, independent of the anatomical origin of the cancer. This finding is in agreement with the suggestion that tumor progression is rapid in UPA patients, limiting the chance of clonal divergence. The identification of 2 groups of UPAs with either a high or low FALI indicates that chromosomal instability is not the only driving force behind early tumor cell dissemination. Thus, other molecular mechanisms must underlie the common biology of these tumors. (c) 2008 Wiley-Liss, Inc.



___
Source: http://www.hubmed.org/display.cgi?uids=18561313
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer.
To: mesothelioma77@gmail.com


[1]J Cancer Res Clin Oncol. 2008 Jun 17;
Ruckhäberle E, Karn T, Hanker L, Gätje R, Metzler D, Holtrich U, Kaufmann M, Rody A

PURPOSE: Multidrug resistance (MDR) has been linked to sphingolipid metabolism and preclinical data ascribe glucosylceramide synthase (GCS) a major role for MDR especially in breast cancer cells but no profound data are available on the expression of this potential therapeutic target in clinical breast cancer specimens. METHODS: We analyzed microarray data of GCS expression in a large cohort of 1,681 breast tumors. RESULTS: Expression of GCS was associated with a positive estrogen receptor (ER) status, lower histological grading, low Ki67 levels and ErbB2 negativity (P

___
Source: http://www.hubmed.org/display.cgi?uids=18560890
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Modified radical mastectomy with axillary dissection using the electrothermal bipolar vessel sealing system.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Modified radical mastectomy with axillary dissection using the electrothermal bipolar vessel sealing system.
To: mesothelioma77@gmail.com


[1]Arch Surg. 2008 Jun; 143(6): 575-80; discussion 581
Manouras A, Markogiannakis H, Genetzakis M, Filippakis GM, Lagoudianakis EE, Kafiri G, Filis K, Zografos GC

HYPOTHESIS: The use of the electrothermal bipolar vessel sealing system is feasible, safe, and effective in modified radical mastectomy with axillary dissection in terms of lymph vessel sealing, hemostasis, and perioperative complications. DESIGN: Prospective study. SETTING: University surgical department. PATIENTS: Between January 1, 2003, and December 31, 2003, 60 patients with locally advanced breast cancer (T2 or T3) admitted for modified radical mastectomy with axillary dissection were included in this study. The entire procedure was performed by the same surgical team using the electrothermal bipolar vessel sealing system. MAIN OUTCOME MEASURES: Final outcome, operative time, hospitalization stay duration, intraoperative blood loss, postoperative mastectomy and axillary drainage volume and duration, and postoperative complications (seroma, bleeding, skin burn, hematoma, lymphedema, pneumothorax, and wound infection or necrosis). RESULTS: The mean (SD) intraoperative blood loss was 45 (12) mL, and the mean (SD) operative time was 105 (7) minutes. No postoperative bleeding, seroma, hematoma, lymphedema, or other complications occurred. The mean (SD) mastectomy and axillary drainage volumes were 20 (8) and 155 (35) mL, respectively, and the mean (SD) drainage durations were 1.3 (0.2) and 2.7 (0.5) days, respectively. The mean (SD) hospital stay was 3.7 (0.6) days. CONCLUSIONS: In this first report (to our knowledge) of modified radical mastectomy with axillary dissection using the electrothermal bipolar vessel sealing system, the technique was feasible, safe, and effective. The device simplified the surgical procedure, while achieving efficient lymph vessel sealing and hemostasis. Compared with historical data regarding the conventional or harmonic scalpel, this technique seems to result in reduced operative time, perioperative blood loss, drainage volume and duration, and incidence of seroma or lymphedema. Prospective randomized controlled studies are necessary to evaluate the effect of this technique on perioperative complications.



___
Source: http://www.hubmed.org/display.cgi?uids=18559751
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Researchers Optimistic About New Therapy For Lung Cancer (Medical News Today)



---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Researchers Optimistic About New Therapy For Lung Cancer (Medical News Today)
To: mesothelioma77@gmail.com


An article in the July edition of The Lancet Oncologysuggests that a common treatment for liver cancer - radiofrequencyablation - can also be used to treat lung cancer. A team of Europeanand American researchers calls for randomized controlled trials inorder to more robustly investigate this minimally invasive procedurefor cancer treatment.

Fri, 20 Jun 2008 08:15:52 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11netr8lv/*http%3A//www.medicalnewstoday.com/articles/112052.php
--
 
 

Fwd: Antihormone therapy in recurrent metastatic breast cancer.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Antihormone therapy in recurrent metastatic breast cancer.
To: mesothelioma77@gmail.com


[1]JAMA. 2008 Jun 18; 299(23): 2745; author reply 2745
Pritchard KI





___
Source: http://www.hubmed.org/display.cgi?uids=18559999
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Non-Surgical Approach Can Treat Lung Cancers (HealthDay via Yahoo! News)



---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Non-Surgical Approach Can Treat Lung Cancers (HealthDay via Yahoo! News)
To: mesothelioma77@gmail.com


WEDNESDAY, June 18 (HealthDay News) -- A minimally invasive procedure normally used to treat liver cancer also holds promise for lung cancer patients, according to a new study.

Wed, 18 Jun 2008 13:01:32 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=12menkona/*http%3A//news.yahoo.com/s/hsn/20080618/hl_hsn/nonsurgicalapproachcantreatlungcancers
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Epigenomics Successfully Completes Larger Clinical Study in Early Lung Cancer Detection (PrimeNewswire via Yahoo! Finance)



---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Epigenomics Successfully Completes Larger Clinical Study in Early Lung Cancer Detection (PrimeNewswire via Yahoo! Finance)
To: mesothelioma77@gmail.com


BERLIN and SEATTLE, June 18, 2008 -- Epigenomics AG , a molecular diagnostics company focusing on the development and commercialization of products for cancer detection based on DNA methylation, today announced that it successfully completed a larger clinical study in its lung cancer program.

Wed, 18 Jun 2008 07:12:56 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11eqctkpc/*http%3A//biz.yahoo.com/pz/080618/144892.html
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Friday, June 20, 2008

Fwd: Sulforaphane inhibited expression of hypoxia-inducible factor-1alpha in human tongue squamous cancer cells and prostate cancer cells.



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Sulforaphane inhibited expression of hypoxia-inducible factor-1alpha in human tongue squamous cancer cells and prostate cancer cells.
To: mesothelioma77@gmail.com


[1]Int J Cancer. 2008 Jun 17;
Yao H, Wang H, Zhang Z, Jiang BH, Luo J, Shi X

Previous studies show that a number of natural compounds from our diet have anticancer effects. Sulforaphane is the most characterized isothiocyanates (ITCs), which are identified in cruciferous vegetables. Sulforaphane is viewed as a conceptually promising agent in cancer prevention. Because of its ability to induce cancer cell apoptosis, it inhibits progression of benign tumors to malignant tumors and interrupts metastasis. However, the effect of sulforaphane on tongue cancer cell proliferation has not yet been reported, and the mechanisms that sulforaphane inhibits cancer development are still unclear. Hypoxia-inducible factor 1 (HIF-1) expression is associated with tumorigenesis and angiogenesis. It regulates the expression of many genes including vascular endothelial growth factor (VEGF), inducible nitric oxide synthase, and lactate dehydrogenase A. In our study, we investigated the effects of sulforaphane on expression of hypoxia-inducible factor-1alpha (HIF-1alpha), which was overexpressed in many human malignant tumors, human tongue squamous cell carcinoma and prostate cancer DU145 cells. Sulforaphane inhibited hypoxia induced expression of HIF-1alpha via inhibiting synthesis of HIF-1alpha. Sulforaphane was also found to inhibit hypoxia induced HIF-1alpha expression through activating JNK and ERK signaling pathways, but not AKT pathway. Inhibition of HIF-1alpha by sulforaphane resulted in decreasing expression of VEGF. Taken together, these results suggest that sulforaphane is an effective chemopreventive compound against tongue cancers and prostate cell angiogenesis in vitro, and that the HIF-1alpha target provides a new sight into the mechanisms of sulforaphane's inhibition against tumor cell proliferation. (c) 2008 Wiley-Liss, Inc.



___
Source: http://www.hubmed.org/display.cgi?uids=18561315
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Psychological distress and its correlates in ovarian cancer: a systematic review.



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Psychological distress and its correlates in ovarian cancer: a systematic review.
To: mesothelioma77@gmail.com


[1]Psychooncology. 2008 Jun 17;
Arden-Close E, Gidron Y, Moss-Morris R

Objective: Ovarian cancer is often diagnosed at an advanced stage, and consequently high levels of distress are often experienced. It is necessary to understand the factors associated with psychological distress in order to guide interventions to target those factors. The purpose of this systematic review was therefore to identify correlates of psychological distress in ovarian cancer.Methods: Included studies had to be quantitative and empirical, with standardized measures of psychological distress (anxiety or depression), and to present results for ovarian cancer patients specifically. Standard systematic search methods were used. Information about design, ovarian cancer sample size, disease stage, time since diagnosis, measures of distress used and findings was extracted from each study. The studies were quality assessed using experimenter-defined criteria as good, average and poor quality. Strength of the evidence (strong, some, inconclusive) was based on the quality and consistency of findings.Results: Eighteen studies meeting the inclusion criteria were identified. There was strong evidence for a relationship between younger age, being diagnosed with more advanced disease, more physical symptoms and shorter time since diagnosis with increased levels of anxiety and/or depression. Additional factors (e.g. immune) tested in a few studies also emerged as correlates of distress.Conclusions: Demographic, disease and quality of life factors correlated with distress. However, too few studies assessed possible psychological and immunological correlates, which could be potentially modified and should be assessed in future studies. Copyright (c) 2008 John Wiley & Sons, Ltd.



___
Source: http://www.hubmed.org/display.cgi?uids=18561287
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Ex-BBC presenter has lung cancer (BBC News)



---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Ex-BBC presenter has lung cancer (BBC News)
To: mesothelioma77@gmail.com


Former BBC Wales sports presenter Bob Humphrys says his lung cancer diagnosis seems "rather unjust".

Tue, 17 Jun 2008 15:20:34 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11phpkfg0/*http%3A//news.bbc.co.uk/go/rss/-/1/hi/wales/7459477.stm
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Heterogeneity of drug target expression among metastatic lesions: lessons from a breast cancer autopsy program.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Heterogeneity of drug target expression among metastatic lesions: lessons from a breast cancer autopsy program.
To: mesothelioma77@gmail.com


[1]Clin Cancer Res. 2008 Jun 15; 14(12): 3643-5
Steeg PS





___
Source: http://www.hubmed.org/display.cgi?uids=18559575
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Suppression of tumor growth and angiogenesis by a specific antagonist of the cell-surface expressed nucleolin.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Suppression of tumor growth and angiogenesis by a specific antagonist of the cell-surface expressed nucleolin.
To: mesothelioma77@gmail.com


[1]PLoS ONE. 2008; 3(6): e2518
Destouches D, El Khoury D, Hamma-Kourbali Y, Krust B, Albanese P, Katsoris P, Guichard G, Briand JP, Courty J, Hovanessian AG

BACKGROUND: Emerging evidences suggest that nucleolin expressed on the cell surface is implicated in growth of tumor cells and angiogenesis. Nucleolin is one of the major proteins of the nucleolus, but it is also expressed on the cell surface where is serves as a binding protein for variety of ligands implicated in cell proliferation, differentiation, adhesion, mitogenesis and angiogenesis. METHODOLOGY/PRINCIPAL FINDINGS: By using a specific antagonist that binds the C-terminal tail of nucleolin, the HB-19 pseudopeptide, here we show that the growth of tumor cells and angiogenesis are suppressed in various in vitro and in vivo experimental models. HB-19 inhibited colony formation in soft agar of tumor cell lines, impaired migration of endothelial cells and formation of capillary-like structures in collagen gel, and reduced blood vessel branching in the chick embryo chorioallantoic membrane. In athymic nude mice, HB-19 treatment markedly suppressed the progression of established human breast tumor cell xenografts in nude mice, and in some cases eliminated measurable tumors while displaying no toxicity to normal tissue. This potent antitumoral effect is attributed to the direct inhibitory action of HB-19 on both tumor and endothelial cells by blocking and down regulating surface nucleolin, but without any apparent effect on nucleolar nucleolin. CONCLUSION/SIGNIFICANCE: Our results illustrate the dual inhibitory action of HB-19 on the tumor development and the neovascularization process, thus validating the cell-surface expressed nucleolin as a strategic target for an effective cancer drug. Consequently, the HB-19 pseudopeptide provides a unique candidate to consider for innovative cancer therapy.



___
Source: http://www.hubmed.org/display.cgi?uids=18560571
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Scalp cooling to prevent chemotherapy-induced hair loss: practical and clinical considerations.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Scalp cooling to prevent chemotherapy-induced hair loss: practical and clinical considerations.
To: mesothelioma77@gmail.com


[1]Support Care Cancer. 2008 Jun 17;
Mols F, van den Hurk CJ, Vingerhoets AJ, Breed WP

OBJECTIVE: The objective of this prospective multicenter study was to obtain insight into the severity and burden of hair loss among cancer patients treated with chemotherapy. In addition, we described the effectiveness and burden of scalp cooling and the satisfaction with wigs, with hair regrowth, and with body image. MATERIALS AND METHODS: Breast cancer patients treated with (n = 98) and without (n = 168) scalp cooling completed questionnaires before chemotherapy and 3 weeks and 6 months after completion of chemotherapy. RESULTS: Scalp cooling was effective in preventing chemotherapy-induced hair loss in 32 of 62 available patients (52%). Even though patients knew hair loss was temporary, it was a burden to 54% of them (n = 100). Scalp cooling was a burden for only 17 out of 51 patients (33%). Most patients who used a wig or head cover were satisfied with it (82%, n = 126). Patients were moderately satisfied with the regrowth of their hair after chemotherapy (mean 11.6; SD 2.53; range 0-20). Successfully cooled patients rated their hair as less important for their body image compared to patients who did experience hair loss (p = 0.014). DISCUSSION: Chemotherapy-induced hair loss is perceived as burdensome. It may be prevented by offering scalp cooling which is often an effective method to prevent this form of hair loss and is tolerated well by patients. However, if possible, scalp-cooling techniques should be improved and their effectiveness should be increased because if scalp cooling is unsuccessful, patients' rate their hair loss as more burdensome compared to noncooled patients.



___
Source: http://www.hubmed.org/display.cgi?uids=18560904
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Predicting breast cancer risk: implications of a "weak" family history.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Predicting breast cancer risk: implications of a "weak" family history.
To: mesothelioma77@gmail.com


[1]Fam Cancer. 2008 Jun 17;
Anderson E, Berg J, Black R, Bradshaw N, Campbell J, Cetnarskyj R, Drummond S, Davidson R, Dunlop J, Fordyce A, Gibbons B, Goudie D, Gregory H, Hanning K, Holloway S, Longmuir M, McLeish L, Murday V, Miedzybrodska Z, Nicholson D, Pearson P, Porteous M, Reis M, Slater S, Smith K, Smyth E, Snadden L, Steel M, Stirling D, Watt C, Whyte C, Young D

Published guidelines adopted in many countries recommend that women whose family history of breast cancer places them at a risk >/=1.7 times that of the age-matched general population, should be considered for inclusion in special surveillance programmes. However validation of risk assessment models has been called for as a matter of urgency. The databases of the four Scottish Familial Breast Cancer clinics and the Scottish Cancer Registry have been searched to identify breast cancers occurring among 1,125 women aged 40-56, with family histories placing them below the "moderate" level of genetic risk. The observed incidence over 6 years was compared with age-specific data for the Scottish population. Our findings confirm that when there are two affected relatives (one first degree) the relative risk (RR) exceeds 1.7 regardless of their ages at diagnosis. When only one (first degree) relative was affected at any age from 40 to 55, the RR does not reach 1.7 if that relative was a mother but exceeds it if the relative was a sister. The probable explanation is that sisters are more likely than mother/daughter pairs to share homozygosity for a risk allele. Surveillance programmes might therefore accommodate sisters of women affected before age 55. Evidence that "low penetrance" alleles contributing to breast cancer risk may be recessive should be taken into account in strategies for identifying them.



___
Source: http://www.hubmed.org/display.cgi?uids=18560993
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Thursday, June 19, 2008

Fwd: The next step in reducing the toll of tobacco



---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: The next step in reducing the toll of tobacco
To: mesothelioma77@gmail.com


The Star article, 'Cigarette sales dive 17.8% after tax hike,' and the June 10 editorial regarding the reduction in cigarette sales and the Quit 2 Win campaign explained how the tobacco tax increase has ...

Sun, 15 Jun 2008 07:00:00 GMT


Source: http://www.indystar.com/apps/pbcs.dll/article?AID=2008806150337
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc


Fwd: Philanthropist-activist Stewart Mott dead at 70



---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Philanthropist-activist Stewart Mott dead at 70
To: mesothelioma77@gmail.com


NEW YORK -- Stewart Mott, the Flint-raised eccentric and freethinking philanthropist who helped bankroll the presidential campaigns of Eugene McCarthy and George McGovern, has died.

Sun, 15 Jun 2008 07:00:00 GMT


Source: http://www.freep.com/apps/pbcs.dll/article?AID=2008806150592
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc


Fwd: Olive oil protects rat liver microsomes against benzo(a)pyrene-induced oxidative damages: An in vitro study.



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Olive oil protects rat liver microsomes against benzo(a)pyrene-induced oxidative damages: An in vitro study.
To: mesothelioma77@gmail.com


[1]Mol Nutr Food Res. 2008 Jun 12;
Devi KP, Kiruthiga PV, Pandian SK, Archunan G, Arun S

Benzo(a)pyrene (B(a)P), a member of the polycyclic aromatic hydrocarbon family is present ubiquitously in the environment. One of its toxic effects is induction of oxidative stress (mediated by the enzyme B(a)P hydroxylase) which leads to various diseases like cancer. Olive oil (OO) that consists of many antioxidant compounds is reported to have many beneficial properties including protection against cancer. The objective of the present study is to evaluate the effect of OO on B(a)P hydroxylase enzyme and further elucidate the antioxidant capacity of OO against B(a)P-induced toxicity. Rat liver microsomes were divided into three groups: vehicle control, B(a)P treated group, and OO + B(a)P co-incubated group. Antioxidant enzymes which were decreased and protein carbonyl content and lipid peroxidation products which were increased on exposure to B(a)P was attenuated to near normal on OO exposure. B(a)P hydroxylase enzyme was very low in OO incubated group which may be due to inhibition of the enzyme by OO or high utilization for the metabolism of B(a)P. Further, no B(a)P metabolites (3-OH B(a)P and B(a)P 7,8-dihydrodiol) were identified in HPLC during B(a)P + OO exposure. The results prove the protective role of OO against B(a)P-induced oxidative damage.



___
Source: http://www.hubmed.org/display.cgi?uids=18551459
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Bisulfite modification for analysis of DNA methylation.



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Bisulfite modification for analysis of DNA methylation.
To: mesothelioma77@gmail.com


[1]Curr Protoc Nucleic Acid Chem. 2008 Jun; Chapter 6: Unit 6.10
Hayatsu H, Shiraishi M, Negishi K

Bisulfite is known to deaminate cytosine in nucleic acids, while 5-methylcytosine resists this bisulfite action. For this reason, bisulfite treatment has been used for detecting 5-methylcytosine in DNA, a minor component of eukaryotic DNA, presently recognized as playing an important role in the control of gene function. This procedure, called bisulfite genomic sequencing, is a principal method for the analysis of DNA methylation in various biological phenomena, including human diseases such as cancer. This unit describes an efficient procedure utilizing a newly developed high-concentration bisulfite solution. Protocols for this methodology are supplemented with discussions focused on chemical aspects of the bisulfite treatment.



___
Source: http://www.hubmed.org/display.cgi?uids=18551428
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Visualizing protease activity in living cells: from two dimensions to four dimensions.



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Visualizing protease activity in living cells: from two dimensions to four dimensions.
To: mesothelioma77@gmail.com


[1]Curr Protoc Cell Biol. 2008 Jun; Chapter 4: Unit 4.20
Jedeszko C, Sameni M, Olive MB, Moin K, Sloane BF

Proteolytic degradation of extracellular matrix (ECM) components by cells is an important metabolic activity as cells grow, remodel, and migrate through the ECM. The ability to analyze ECM degradation can be valuable in the study of developmental processes as well as pathologies, such as cancer. In this unit we describe an in vitro live cell-based method to image and quantitatively measure the degradation of ECM components by live cells. Cells are grown in the presence of fluorescent dye-quenched protein substrates (DQ-gelatin, DQ-collagen I, and DQ-collagen IV) that are mixed with protein matrices. Upon proteolytic cleavage, fluorescence is released that directly reflects the level of proteolysis by the cells. Using confocal microscopy and advanced imaging software, the fluorescence is detected and accurate measurements of proteolytic degradation in three and four dimensions can be assessed.



___
Source: http://www.hubmed.org/display.cgi?uids=18551423
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Vitamin D and Sunlight: Strategies for Cancer Prevention and Other Health Benefits.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Vitamin D and Sunlight: Strategies for Cancer Prevention and Other Health Benefits.
To: mesothelioma77@gmail.com


[1]Clin J Am Soc Nephrol. 2008 Jun 11;
Holick MF

Vitamin D deficiency is a worldwide health problem. The major source of vitamin D for most humans is sensible sun exposure. Factors that influence cutaneous vitamin D production include sunscreen use, skin pigmentation, time of day, season of the year, latitude, and aging. Serum 25-hydroxyvitamin D [25(OH)D] is the measure for vitamin D status. A total of 100 IU of vitamin D raises blood level of 25(OH)D by 1 ng/ml. Thus, children and adults who do not receive adequate vitamin D from sun exposure need at least 1000 IU/d vitamin D. Lack of sun exposure and vitamin D deficiency have been linked to many serious chronic diseases, including autoimmune diseases, infectious diseases, cardiovascular disease, and deadly cancers. It is estimated that there is a 30 to 50% reduction in risk for developing colorectal, breast, and prostate cancer by either increasing vitamin D intake to least 1000 IU/d vitamin D or increasing sun exposure to raise blood levels of 25(OH)D >30 ng/ml. Most tissues in the body have a vitamin D receptor. The active form of vitamin D, 1,25-dihydroxyvitamin D, is made in many different tissues, including colon, prostate, and breast. It is believed that the local production of 1,25(OH)2D may be responsible for the anticancer benefit of vitamin D. Recent studies suggested that women who are vitamin D deficient have a 253% increased risk for developing colorectal cancer, and women who ingested 1500 mg/d calcium and 1100 IU/d vitamin D3 for 4 yr reduced risk for developing cancer by >60%.



___
Source: http://www.hubmed.org/display.cgi?uids=18550652
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: The effects of surgery on tumor growth: a century of investigations.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: The effects of surgery on tumor growth: a century of investigations.
To: mesothelioma77@gmail.com


[1]Ann Oncol. 2008 Jun 10;
Demicheli R, Retsky MW, Hrushesky WJ, Baum M, Gukas ID

A few clinical investigations suggest that while primary breast cancer surgical removal favorably modifies the natural history for some patients, it may also hasten the metastatic development for others. The concepts underlying this disease paradigm, i.e. tumor homeostasis, tumor dormancy and surgery-driven enhancement of metastasis development, have a long history that is reviewed. The review reveals the context in which these concepts were conceived and structured to explain experimental data and shows that they are not so new and far fetched. The idea that surgical cancer resection has both beneficial and adverse effects upon cancer spread and growth that result from the modulation of tumor dormancy by the resection should be considered a potentially fruitful working hypothesis.



___
Source: http://www.hubmed.org/display.cgi?uids=18550576
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Gene test that can show if cancer drugs will cure you (Daily Mail)



---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Mon, Jun 16, 2008 at 10:45 PM
Subject: Gene test that can show if cancer drugs will cure you (Daily Mail)
To: mesothelioma77@gmail.com


For years, cancer doctors have known that many patients aren't helped by the drugs they're given. For instance, only 20 per cent of those with advanced lung cancer will benefit from certain drugs.

Tue, 17 Jun 2008 00:46:44 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=133t4tc4r/*http%3A//www.dailymail.co.uk/health/article-1026987/Gene-test-cancer-drugs-cure-you.html?ITO=1490
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Palace of Westminster Asbestos Problem Ignored (PR Newswire via Yahoo! Finance)



---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Mon, Jun 16, 2008 at 10:45 PM
Subject: Palace of Westminster Asbestos Problem Ignored (PR Newswire via Yahoo! Finance)
To: mesothelioma77@gmail.com


Clinica - the world's leading news service for the medical technology industry - has learned that staff and visitors to London's Houses of Parliament have been at risk of exposure to high levels of asbestos contamination for significant periods during the last three years.

Mon, 16 Jun 2008 15:42:00 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=121h52kcg/*http%3A//biz.yahoo.com/prnews/080616/3681925en_public.html?.v=1
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Ability to track stem cells in tumors could advance cancer treatments



---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Mon, Jun 16, 2008 at 10:45 PM
Subject: Ability to track stem cells in tumors could advance cancer treatments
To: mesothelioma77@gmail.com


Using noninvasive molecular imaging technology, a method has been developed to track the location and activity of mesenchymal stem cells in the tumors of living organisms, according to researchers at SNM's 55th ...

Tue, 17 Jun 2008 01:10:43 GMT


Source: http://www.biologynews.net/archives/2008/06/16/ability_to_track_stem_cells_in_tumors_could_advance_cancer_treatments.html
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc


Wednesday, June 18, 2008

Fwd: Low phosphorylation of ER{alpha} serine 118 and high phosphorylation of ER{alpha} serine 167 improve survival in ER-positive breast cancer.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Low phosphorylation of ER{alpha} serine 118 and high phosphorylation of ER{alpha} serine 167 improve survival in ER-positive breast cancer.
To: mesothelioma77@gmail.com


[1]Endocr Relat Cancer. 2008 Jun 12;
Yamashita H, Nishio M, Toyama T, Sugiura H, Kondo N, Kobayashi S, Fujii Y, Iwase H

Endocrine therapy has become the most important treatment option for women with estrogen receptor (ER)-positive breast cancer. Urgently needed are prognostic assays that can identify those who need additional adjuvant therapy, such as signal transduction inhibitors or chemotherapy, for ER-positive early breast cancer. We examined phosphorylation of ERalpha serine (Ser) 118, ERalpha Ser167, p44/42 MAPK and Akt, and expression of progesterone receptor (PR), AIB1, HER2, p53 and Ki67 in ER-positive breast cancers by immunohistochemistry, and analyzed their significance for prognosis. Phosphorylation levels of ERalpha Ser118, ERalpha Ser167, MAPK and Akt were positively correlated. AIB1 expression was significantly associated with phosphorylation of ERalpha Ser118, MAPK and Akt, and HER2 expression. Low phosphorylation of ERalpha Ser118 and high phosphorylation of ERalpha Ser167 were associated with significantly improved disease-free (P = 0.0003 and P = 0.0002, respectively) and overall survival (P = 0.0007 and P = 0.0016, respectively) in multivariate analyses. Our data suggest that phosphorylation of ERalpha Ser118 and ERalpha Ser167 affects survival in ER-positive breast cancer and could be helpful in distinguishing patients who are likely to benefit from endocrine therapy alone from those who are not.



___
Source: http://www.hubmed.org/display.cgi?uids=18550720
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Axillary recurrence in sentinel lymph node-negative breast cancer patients.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Axillary recurrence in sentinel lymph node-negative breast cancer patients.
To: mesothelioma77@gmail.com


[1]Ann Oncol. 2008 Jun 10;
Poletti P, Fenaroli P, Milesi A, Paludetti A, Mangiarotti S, Virotta G, Candiago E, Bettini A, Caremoli ER, Labianca R, Tondini C

BACKGROUND: Sentinel lymph node biopsy (SLNB) was developed to axillary lymph node dissection (ALND) in the treatment of breast cancer. SLNB is predictive of axillary node status. Major concern is the occurrence of a false-negative SLN. Purpose of this study is to determine the rate of axillary recurrence in our series of unselected patients. PATIENTS AND METHODS: All patients with a negative SLNB from November 1999 to December 2006 have been treated and followed at our unit. Information on patients' characteristics, treatment and follow-up has been collected. RESULTS: Eight-hundred and four patients with negative SLNB did not receive ALND. After a median follow-up of 38.8 months, 21 patients had distant metastases, four had axillary relapse, nine had an in-breast recurrence and two had both. All patients with axillary recurrence received axillary dissection and systemic adjuvant therapy. They are all presently alive and free from disease. CONCLUSION: Data from this series, the largest from a general hospital, showed that isolated axillary node recurrence after negative SLNB is rare (

___
Source: http://www.hubmed.org/display.cgi?uids=18550574
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Chemotherapy in breast cancer patients with brain metastases: Have new chemotherapic agents changed the clinical outcome?



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Chemotherapy in breast cancer patients with brain metastases: Have new chemotherapic agents changed the clinical outcome?
To: mesothelioma77@gmail.com


[1]Crit Rev Oncol Hematol. 2008 Jun 10;
Tosoni A, Franceschi E, Brandes AA

Brain metastasis occurs in 15-40% of cancer patients and is present in approximately 10-16% of patients with metastatic breast disease. However, little is known about prognostic factors enabling the early identification of breast cancer patients at risk of CNS metastases. Therapy for brain metastases should be based on several parameters, such as the assessment of prognostic variables, the extent of neurological and systemic disease, and its chemo-sensitivity to previously administered chemotherapy treatments. In view of the known close correlation between metastatic and primary tumor chemosensitivity, the type of chemotherapy chosen should depend more on the tumor histology than on the cerebral distribution of the single drug. More recent drugs with a high impact on the clinical outcome of metastatic breast cancer patients, such as taxanes or trastuzumab, play only a limited role in the treatment of brain metastases.



___
Source: http://www.hubmed.org/display.cgi?uids=18550383
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Processing of clustered DNA damage in human breast cancer cells MCF-7 with partial DNA-PKcs deficiency.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Processing of clustered DNA damage in human breast cancer cells MCF-7 with partial DNA-PKcs deficiency.
To: mesothelioma77@gmail.com


[1]Cancer Lett. 2008 Jun 10;
Peddi P, Francisco DC, Cecil AM, Hair JM, Panayiotidis MI, Georgakilas AG

Complex DNA damage such as double strand breaks (DSBs) and non-DSB bistranded oxidative clustered DNA lesions (OCDL) (two or more DNA lesions within a short DNA fragment of 1-10bp on opposing DNA strands) are considered the hallmark of ionizing radiation. Clustered DNA lesions are hypothesized to be repair-resistant lesions challenging the repair mechanisms of the cell. The DNA-dependent protein kinase catalytic subunit (DNA-PKcs) plays an important role during the processing of DSBs. To evaluate the role of DNA-PKcs in the processing of complex DNA damage in human MCF-7 breast cancer cells we used small interfering RNAs (siRNAs) to target the silencing of the gene Prkdc coding for DNA-PKcs. MCF-7 cells with knockdown DNA-PKcs expression showed a marked decrease in their efficiency to process DSBs and OCDL after exposure to radiotherapy-relevant gamma ray doses. For the detection and measurement of complex DSBs and OCDL, we used the gamma-H2AX assay and an adaptation of pulsed field gel electrophoresis with Escherichia coli repair enzymes as DNA damage probes. An accumulation of all types of DNA damage was detected for the siRNA-treated MCF-7 cells compared to controls. These findings point to the important role of DNA-PKcs in the processing of complex DNA damage and its potential association with breast cancer development.



___
Source: http://www.hubmed.org/display.cgi?uids=18550272
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Lung Cancer Alliance Praises State Senate Action in Georgia



---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Mon, Jun 16, 2008 at 10:45 PM
Subject: Lung Cancer Alliance Praises State Senate Action in Georgia
To: mesothelioma77@gmail.com


Lung Cancer Alliance-Georgia Advocates Acknowledged with Resolution WASHINGTON, June 16 /PRNewswire-USNewswire/ -- Today, Lung Cancer Alliance praised Georgia State Senators John Wiles , Chip Rogers , Judson ...

Tue, 17 Jun 2008 00:29:19 GMT


Source: http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/06-16-2008/0004833342&EDATE=
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc


Fwd: Women more likely to get lung cancer (WPBN Traverse City)



---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Mon, Jun 16, 2008 at 10:45 PM
Subject: Women more likely to get lung cancer (WPBN Traverse City)
To: mesothelioma77@gmail.com


Posted: Monday, June 16, 2008 at 5:46 a.m. Although cigarette smoking causes an estimated 90 percent of lung cancer cases some patients have never smoked.

Mon, 16 Jun 2008 09:59:27 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11n08eemm/*http%3A//www.tv7-4.com/news/news_story.aspx?id=147297
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: NIAGARA FALLS: OSHA fines Memorial Medical Center (Niagara Gazette)



---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Mon, Jun 16, 2008 at 10:45 PM
Subject: NIAGARA FALLS: OSHA fines Memorial Medical Center (Niagara Gazette)
To: mesothelioma77@gmail.com


A federal labor agency has levied a fine against Niagara Falls Memorial Medical Center for failing to adequately protect construction workers from asbestos exposure during a renovation project last year. The U.S. Department of Labor's Occupational Safety and Health Administration ordered the medical facility to pay $110,000 in fines for failing to provide proper employee safeguards during a ...

Tue, 17 Jun 2008 00:59:38 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=123vj199n/*http%3A//www.niagara-gazette.com/local/local_story_168204856.html
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Anita Mui's Mom loses court fight over $100m estate



---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Mon, Jun 16, 2008 at 10:45 PM
Subject: Anita Mui's Mom loses court fight over $100m estate
To: mesothelioma77@gmail.com


The mother of the late Cantopop diva Anita Mui Yim-fong yesterday lost her legal battle to wrest control of her daughters estimated HK$100 million estate.

Mon, 16 Jun 2008 20:06:08 GMT


Source: http://www.thestandard.com.hk/news_detail.asp?pp_cat=30&art_id=67322&sid=19373075&con_type=1
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc


Tuesday, June 17, 2008

Fwd: Lesbians and cancer: an overlooked health disparity.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Lesbians and cancer: an overlooked health disparity.
To: mesothelioma77@gmail.com


[1]Cancer Causes Control. 2008 Jun 13;
Brown JP, Tracy JK

OBJECTIVE: To evaluate the breast, cervical, ovarian, lung, and colorectal cancer literatures using a novel application of the cancer disparities grid to identify disparities along domains of the cancer continuum focusing on lesbians as a minority population. METHODS: Computerized databases were searched for articles published from 1981 to present. Cumulative search results identified 51 articles related to lesbians and disparities, which were classified by domain. RESULTS: The majority of articles identified were related to breast and cervical cancer screening. Barriers to adequate screening for both cancers include personal factors, poor patient-provider communication, and health care system factors. Tailored risk counseling has been successful in increasing lesbian's mammography and Pap screening. Ovarian, lung, and colorectal cancer have been virtually unexplored in this population. An "Adjustment to Illness/Quality of Life" domain was added to capture literature on psychosocial aspects of cancer. CONCLUSIONS: This review revealed a lack of research for specific cancers and for specific aspects of the cancer continuum. The limited number of studies identified focused on issues related to screening/prevention in cervical and breast cancers, with almost no attention to incidence, etiology, diagnosis, treatment, survival, morbidity, or mortality. We present implications for social and public health policy, research, and prevention.



___
Source: http://www.hubmed.org/display.cgi?uids=18551371
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity.
To: mesothelioma77@gmail.com


[1]Pharmacogenet Genomics. 2008 Jul; 18(7): 623-31
Fan L, Goh BC, Wong CI, Sukri N, Lim SE, Tan SH, Guo JY, Lim R, Yap HL, Khoo YM, Iau P, Lee HS, Lee SC

OBJECTIVES: Doxorubicin is a cytotoxic drug with potential for severe myelosuppression that is highly variable and poorly predictable. METHODS: We correlated CBR1 and CBR3 genotypes with the pharmacokinetics and pharmacodynamics of doxorubicin in 101 Southeast Asian breast cancer patients receiving first-line doxorubicin. RESULTS: A common CBR3 11G>A variant was associated with lower doxorubicinol area under the concentration-time curve (AUC)/doxorubicin AUC metabolite ratio (P=0.009, GG vs. AA; trend test, P=0.004), lower CBR3 expression in breast tumor tissue (P=0.001, GG vs. AA), greater tumor reduction (P=0.015, GG vs. AA), and greater percentage reduction of leukocyte and platelet counts at nadir (trend test, PA variant than Indians (PA was associated with higher doxorubicinol AUC (P=0.009, GG vs. AA) and CBR3 expression in breast tumor tissue (P=0.001, GG vs AA). CONCLUSION: Polymorphisms in CBR3 may explain interindividual and interethnic variability of doxorubicin pharmacokinetics and pharmacodynamics.



___
Source: http://www.hubmed.org/display.cgi?uids=18551042
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Polymorphisms in predicted microRNA binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Polymorphisms in predicted microRNA binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker.
To: mesothelioma77@gmail.com


[1]Carcinogenesis. 2008 Jun 10;
Brendle A, Lei H, Brandt A, Johansson R, Enquist K, Henriksson R, Hemminki K, Lenner P, Försti A

Integrins control the cell attachment to the extracellular matrix (ECM) and play an important role in mediating cell proliferation, migration and survival. A number of important cancer-associated integrin genes can be regulated by microRNAs (miRNAs) that bind to their target sites in the 3' untranslated regions (UTRs). We examined the effect of single nucleotide polymorphisms (SNPs) in predicted miRNA taget sites of six integrin genes (ITGA3, ITGA6, ITGAv, ITGB3, ITGB4, ITGB5) on breast cancer (BC) risk and clinical outcome. Six SNPs were genotyped in 749 Swedish incident BC cases with detailed clinical data and up to 15 years of follow-up together with 1493 matched controls. We evaluated associations between genotypes and BC risk and clinical tumour characteristics. Survival probabilities were compared between different subgroups. As a novel finding several SNPs seemed to associate with the hormone receptor status. The strongest association was observed between the A allele of the SNP rs743554 in the ITGB4 gene and estrogen receptor negative (ER-) tumours (odds ratio [OR] 2.09, 95% confidence intervals [CIs] 1.19-3.67). The same SNP was associated with survival. The A allele carriers had a worse survival compared to the wild type genotype carriers (hazard ratio [HR] 2.11 95% CIs 1.21-3.68). The poor survival was significantly associated with the aggressive tumour characteristics: high grade, lymph node metastasis and high stage. None of the SNPs was significantly associated with BC risk. As the ITGB4 SNP seems to influence tumour aggressiveness and survival, it may have prognostic value in the clinic.



___
Source: http://www.hubmed.org/display.cgi?uids=18550570
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Women Get Lung Cancer From Smoking at Same Rates as Men (MedicineNet.com)



---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Mon, Jun 16, 2008 at 10:45 PM
Subject: Women Get Lung Cancer From Smoking at Same Rates as Men (MedicineNet.com)
To: mesothelioma77@gmail.com


Title: Women Get Lung Cancer From Smoking at Same Rates as Men Category: Health News Created: 6/15/2008 2:00:00 AM Last Editorial Review: 6/16/2008

Mon, 16 Jun 2008 19:35:35 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=124fk3sul/*http%3A//www.medicinenet.com/guide.asp?s=rss&k=DailyHealth&a=90299
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: False-positive sentinel lymph nodes in breast cancer patients caused by benign glandular inclusions: report of three cases and review of the literature.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: False-positive sentinel lymph nodes in breast cancer patients caused by benign glandular inclusions: report of three cases and review of the literature.
To: mesothelioma77@gmail.com


[1]Am J Clin Pathol. 2008 Jul; 130(1): 21-7
Peng Y, Ashfaq R, Ewing G, Leitch AM, Molberg KH

We report 3 cases of sentinel lymph nodes (SLNs) containing benign glandular inclusions (BGIs) in patients with breast carcinoma that were initially misdiagnosed as metastatic carcinoma.The first case had an SLN with glandular elements adjacent to a squamous inclusion cyst, the second had an SLN with a single complex gland showing apocrine features, and the third had 2 SLNs, each containing rare glands lined by bland columnar cells and surrounded by thin, fibrous bands. All glandular elements were distinctly different from the corresponding invasive carcinoma. Immunostains for myoepithelial markers revealed smooth muscle myosin reactivity and scattered p63+ nuclei, indicating the presence of myoepithelial cells. Based on morphologic and immunohistochemical findings, a diagnosis of BGIs was established.Our case series report indicates that comparison with the morphologic features of primary breast carcinoma and using immunohistochemical analysis for myoepithelial markers are important ancillary tools in distinguishing BGIs from metastatic carcinoma.



___
Source: http://www.hubmed.org/display.cgi?uids=18550466
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Healthwatch for June 16, 2008



---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Mon, Jun 16, 2008 at 10:45 PM
Subject: Healthwatch for June 16, 2008
To: mesothelioma77@gmail.com


Posted Monday, June 16, 2008 ; 01:06 PM Updated Monday, June 16, 2008 ; 05:45 PM The FDA says it found the source of a salmonella outbreak, strong evidence links traffic pollution to childhood allergies and ...

Tue, 17 Jun 2008 02:34:59 GMT


Source: http://www.wvnstv.com/story.cfm?func=viewstory&storyid=40077
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc


Fwd: Cancer-sniffing dogs



---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Mon, Jun 16, 2008 at 10:45 PM
Subject: Cancer-sniffing dogs
To: mesothelioma77@gmail.com


A South Korean firm said it has successfully cloned four dogs capable of sniffing out human cancers by using tissue from a retriever in Japan.

Tue, 17 Jun 2008 00:11:49 GMT


Source: http://www.dailytimes.com.pk/default.asp?page=2008\06\17\story_17-6-2008_pg9_9
--
 
~
Powered by RssFwd, a service of Blue Sky Factory, Inc


Fwd: Even revolutionaries have to moisturize



---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Mon, Jun 16, 2008 at 10:45 PM
Subject: Even revolutionaries have to moisturize
To: mesothelioma77@gmail.com


No other organ would stand for this kind of abuse. Men cut it, scrape it, sunburn it and generally abuse it every day.

Mon, 16 Jun 2008 23:02:22 GMT


Source: http://www.canada.com/saskatoonstarphoenix/story.html?id=84a48359-3f46-4581-99e1-38e4112a4544
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc


Fwd: Palace of Westminster Asbestos Problem Ignored



---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Mon, Jun 16, 2008 at 10:45 PM
Subject: Palace of Westminster Asbestos Problem Ignored
To: mesothelioma77@gmail.com


Clinica - the world's leading news service for the medical technology industry - has learned that staff and visitors to London's Houses of Parliament have been at risk of exposure to high levels of asbestos ...

Mon, 16 Jun 2008 20:00:29 GMT


Source: http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/06-16-2008/0004833087&EDATE=
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc


Fwd: Palace of Westminster Asbestos Problem Ignored



---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Mon, Jun 16, 2008 at 10:45 PM
Subject: Palace of Westminster Asbestos Problem Ignored
To: mesothelioma77@gmail.com


Clinica - the world's leading news service for the medical technology industry - has learned that staff and visitors to London's Houses of Parliament have been at risk of exposure to high levels of asbestos ...

Mon, 16 Jun 2008 20:00:29 GMT


Source: http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/06-16-2008/0004833087&EDATE=
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc


Fwd: Genetic variation in DNA repair pathway genes and premenopausal breast cancer risk.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Genetic variation in DNA repair pathway genes and premenopausal breast cancer risk.
To: mesothelioma77@gmail.com


[1]Breast Cancer Res Treat. 2008 Jun 13;
Han J, Haiman C, Niu T, Guo Q, Cox DG, Willett WC, Hankinson SE, Hunter DJ

Purpose We comprehensively evaluated genetic variants in DNA repair genes with premenopausal breast cancer risk. Methods In this nested case-control study of 239 prospectively ascertained premenopausal breast cancer cases and 477 matched controls within the Nurses' Health Study II, we evaluated 1,463 genetic variants in 60 candidate genes across five DNA repair pathways, along with DNA polymerases, Fanconi Anemia complementation groups, and other related genes. Results Four variants were associated with breast cancer risk with a significance level of

___
Source: http://www.hubmed.org/display.cgi?uids=18551366
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Monday, June 16, 2008

Fwd: Poly-MVA - The First Dietary Supplement To Be Cleared By The FDA For Use In A Cancer Study



---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Poly-MVA - The First Dietary Supplement To Be Cleared By The FDA For Use In A Cancer Study
To: mesothelioma77@gmail.com


Main Category: Cancer / Oncology Also Included In: Complementary Medicine / Alternative Medicine Article Date: 15 Jun 2008 - 3:00 PDT CancerAssistanceCenter.org announces the immediate availability of free ...

Sun, 15 Jun 2008 10:00:00 GMT


Source: http://www.medicalnewstoday.com/articles/111306.php
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc


Fwd: Westville mayor dies after battling lung cancer



---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Westville mayor dies after battling lung cancer
To: mesothelioma77@gmail.com


Westville Mayor Michael Galbraith died Friday afternoon an almost four-year bout with lung cancer, according to officials.

Sun, 15 Jun 2008 07:00:00 GMT


Source: http://www.courierpostonline.com/apps/pbcs.dll/article?AID=2008806150349
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc


Fwd: Practical Prevention: Lower Cancer Risk By Limiting Red Meat



---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Practical Prevention: Lower Cancer Risk By Limiting Red Meat
To: mesothelioma77@gmail.com


If you're like most Americans, your daily menu contains a lot of meat. You may have sausage or bacon with breakfast.

Sun, 15 Jun 2008 07:28:48 GMT


Source: http://www.kitsapsun.com/news/2008/jun/15/practical-prevention-lower-cancer-risk-by-red/
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc


Fwd: Prospective study of bone scintigraphy as a staging investigation for oesophageal carcinoma.



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Prospective study of bone scintigraphy as a staging investigation for oesophageal carcinoma.
To: mesothelioma77@gmail.com


[1]Br J Surg. 2008 Jun 12; 95(7): 840-844
Jennings NA, Griffin SM, Lamb PJ, Preston S, Richardson D, Karat D, Hayes N

BACKGROUND:: About 10 per cent of patients undergoing radical oesophagectomy for transmural (T3) carcinoma with lymph node involvement (N1) develop symptomatic bone metastases within 12 months of surgery. The aim of this study was to evaluate the introduction of targeted preoperative bone scintigraphy. METHODS:: Of 790 patients with oesophageal carcinoma staged between December 2000 and December 2004, 189 were eligible for potentially curative treatment. (99m)Tc-labelled hydroxymethylene diphosphonate bone scintigraphy was performed in those with stage T3 N1 disease (identified by computed tomography and endoscopic ultrasonography) who were suitable for radical treatment. RESULTS:: A total of 115 patients had bone scintigraphy. The histological diagnosis was adenocarcinoma in 82 patients and squamous cell carcinoma in 33. Bone scintigraphy was normal or showed degenerative changes in 93 patients, and abnormal requiring further investigation in 22. Plain radiography, magnetic resonance imaging and biopsy confirmed the presence of bone metastases in 11 patients (9.6 per cent). CONCLUSION:: Bone is frequently the first site of identifiable distant metastatic spread, and bone scintigraphy is recommended to exclude metastatic disease before radical treatment of advanced oesophageal carcinoma. Copyright (c) 2008 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.



___
Source: http://www.hubmed.org/display.cgi?uids=18551472
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Mutational analysis of genes p14ARF, p15INK4b, p16INK4a, and PTEN in human nervous system tumors.



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Mutational analysis of genes p14ARF, p15INK4b, p16INK4a, and PTEN in human nervous system tumors.
To: mesothelioma77@gmail.com


[1]Genet Mol Res. 2008; 7(2): 451-9
Almeida LO, Custódio AC, Araújo JJ, Rey JA, Almeida JR, Santos MJ, Clara CA, Casartelli C

Cancer is one of the most common and severe problems in clinical medicine, and nervous system tumors represent about 2% of the types of cancer. The central role of the nervous system in the maintenance of vital activities and the functional consequences of the loss of neurons can explain how severe brain cancers are. The cell cycle is a highly complex process, with a wide number of regulatory proteins involved, and such proteins can suffer alterations that transform normal cells into malignant ones. The INK4 family members (CDK inhibitors) are the cell cycle regulators that block the progression of the cycle through the R point, causing an arrest in G1 stage. The p14ARF (alternative reading frame) gene is a tumor suppressor that inhibits p53 degradation during the progression of the cell cycle. The PTEN gene is related to the induction of growth suppression through cell cycle arrest, to apoptosis and to the inhibition of cell adhesion and migration. The purpose of the present study was to assess the mutational state of the genes p14ARF, p15INK4b, p16INK4a, and PTEN in 64 human nervous system tumor samples. Homozygous deletions were found in exon 2 of the p15INK4b gene and exon 3 of the p16INK4a gene in two schwannomas. Three samples showed a guanine deletion (63 codon) which led to a loss of heterozygosity in the p15 gene, and no alterations could be seen in the PTEN gene. Although the group of patients was heterogeneous, our results are in accordance with other different studies that indicate that homozygous deletion and loss of heterozygosity in the INK4 family members are frequently observed in nervous system tumors.



___
Source: http://www.hubmed.org/display.cgi?uids=18551412
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Bioavailability issues in studying the health effects of plant polyphenolic compounds.



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Bioavailability issues in studying the health effects of plant polyphenolic compounds.
To: mesothelioma77@gmail.com


[1]Mol Nutr Food Res. 2008 Jun 12;
Yang CS, Sang S, Lambert JD, Lee MJ

Polyphenolic compounds are common in the diet and have been suggested to have a number of beneficial health effects including prevention of cancer, cardiovascular disease, diabetes, and others. For some dietary polyphenols, certain benficial effects are suggested by epidemiological studies, some are supported by studies in animal models, and still others are extrapolated from studies in vitro. Because of the relatively poor bioavailability of many of these compounds, the molecular basis of these beneficial effects is not clear. In the present review, we discuss the potential health benefits of dietary polyphenols from the point of view of bioavailability. Tea catechins, curcumin, and proanthocyanidins are used as examples to illustrate some of the problems that need to be resolved. Further research on both the biological activity and bioavailability of dietary polyphenols is needed to properly assess their usefulness for the prevention and treatment of disease.



___
Source: http://www.hubmed.org/display.cgi?uids=18551457
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Pregnancy associated breast cancer.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Pregnancy associated breast cancer.
To: mesothelioma77@gmail.com


[1]Eur J Surg Oncol. 2008 Jun 10;
García-Manero M, Royo MP, Espinos J, Pina L, Alcazar JL, López G

BACKGROUND: Breast carcinoma during pregnancy put the health of the mother in conflict with that of the foetus. The aim is to give optimal treatment to the mother to maximise the chances of survival, whilst minimising the risk of harm of the foetus. We report the epidemiology, pathology, clinical picture, therapeutic management and foetal outcome of pregnant women with breast cancer treated in our institution. PATIENTS AND METHODS: Twenty-two pregnant breast cancer patients were treated in our hospital from January 1996 to October 2006. Parents were surveyed by mail or telephone regarding outcomes of children exposed to chemotherapy in uterus. RESULTS: The treatment of breast cancer pregnancy should conform as closely as possible to standardised protocols for patients without concomitant pregnancy. Most of the patients underwent surgery during pregnancy In four cases diagnosed during the first trimester chemotherapy was initiated during the 10th week when organogenesis period was finished. None of the children exposed to chemotherapy during this trimester presented congenital malformations. All 11 cases diagnosed during second and third trimester were treated with Doxorrubicin, Fluoracil and Cyclophosphamide and four cases were treated with taxanes. No congenital malformations were detected. CONCLUSION: Breast cancer can be treated with FAC chemotherapy during the second and third trimesters without significant complications for the children exposed to chemotherapy in uterus. We report four cases treated with taxanes after the first trimester and no congenital anomalies were observed.



___
Source: http://www.hubmed.org/display.cgi?uids=18550321
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Antrodia camphorata inhibits proliferation of human breast cancer cells in vitro and in vivo.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Antrodia camphorata inhibits proliferation of human breast cancer cells in vitro and in vivo.
To: mesothelioma77@gmail.com


[1]Food Chem Toxicol. 2008 May 4;
Hseu YC, Chen SC, Chen HC, Liao JW, Yang HL

Antrodia camphorata (A. camphorata) has been shown to induce apoptosis in cultured human breast cancer cells (MDA-MB-231). In this study, we report the effectiveness of the fermented culture broth of A. camphorata in terms of tumor regression as determined using both in vitro cell culture and in vivo athymic nude mice models of breast cancer. We found that the A. camphorata treatment decreased the proliferation of MDA-MB-231 cells by arresting progression through the G1 phase of the cell cycle. This cell cycle blockade was associated with reductions in cyclin D1, cyclin E, CDK4, cyclin A, and proliferating cell nuclear antigen (PCNA), and increased CDK inhibitor p27/KIP and p21/WAF1 in a dose and time-dependent manner. Furthermore, the A. camphorata treatment was effective in delaying tumor incidence in the nude mice inoculated with MDA-MB-231 cells as well as reducing the tumor burden when compared to controls. A. camphorata treatment also inhibited proliferation (cyclin D1 and PCNA) and induced apoptosis (Bcl-2 and TUNEL) when the tumor tissue sections were examined histologically and immunohistochemically. These results suggest that the A. camphorata treatment induced cell cycle arrest and apoptosis of human breast cancer cells both in vitro and in vivo.



___
Source: http://www.hubmed.org/display.cgi?uids=18550246
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: First synthesis of 3,16,20-polyoxygenated cholestanes, new cytotoxic steroids from the gorgonian Leptogorgia sarmentosa.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: First synthesis of 3,16,20-polyoxygenated cholestanes, new cytotoxic steroids from the gorgonian Leptogorgia sarmentosa.
To: mesothelioma77@gmail.com


[1]Steroids. 2008 May 3;
Boonananwong S, Kongkathip B, Kongkathip N

Using tigogenin as starting material, (20S)-20-hydroxycholestane-3,6-dione (1), (16S, 20S)-16,20-dihydroxycholestan-3-one (2), (20S)-20-hydroxycholest-1-ene-3,16-dione (3) and (20S)-20-hydroxycholest-4-ene-3,16-dione (4), natural polyoxygenated steroids from the gorgonian, Leptogorgia sarmentosa, were synthesized in four steps. Antitumor activity against three tumor cell lines (breast cancer, MCF7, lung cancer NCI and oral cancer KB) was evaluated. Two compounds (3 and 4) showed strong activity against NCI (IC(50) 6.16 and 10.51muM) and moderate activity against MCF7 and KB, the IC(50) being in the range 30.65-47.22muM. Compound 2 showed moderate activity against NCI (IC(50) 42.68muM) but was inactive against MCF7 and KB whereas compound 1 showed no activity against all tested cells.



___
Source: http://www.hubmed.org/display.cgi?uids=18550136
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Sunday, June 15, 2008

Fwd: Clinical and genetic heterogeneity in patients with mosaic variegated aneuploidy: Delineation of clinical subtypes.



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 13, 2008 at 11:19 PM
Subject: Clinical and genetic heterogeneity in patients with mosaic variegated aneuploidy: Delineation of clinical subtypes.
To: mesothelioma77@gmail.com


[1]Am J Med Genet A. 2008 Jun 11;
García-Castillo H, Vásquez-Velásquez AI, Rivera H, Barros-Núñez P

Mosaic variegated aneuploidy (MVA) is a rare autosomal recessive syndrome related to BUB1B gene mutations and characterized by multiple mosaic aneuploidies, cancer predisposition, and a distinct phenotype. We report on two mildly affected sibs with MVA syndrome but without BUB1B mutation. Both patients exhibited growth retardation, frontal bossing, triangular face and micrognathia but not microcephaly or cancer. Aneuploidies were assessed both in G-banded metaphases from lymphocyte cultures and in interphase nuclei from buccal cells by FISH. Screening of 23 exons and intron-exon boundaries of BUB1B was also carried out. These patients were then compared with other 19 MVA patients screened for BUB1B mutations. Around one half of the cultured lymphocytes from our patients had aneuploidies ranging from nullisomies to heptasomies; the most frequent abnormalities were trisomies (42%) and monosomies (28%). FISH results demonstrated more chromosomal losses than gains. Screening of BUB1B in our two patients failed to identify any mutation. A review of the 21/35 patients screened for BUB1B demonstrated three clinical pictures. Patients with monoallelic BUB1B mutations were severely affected with Dandy-Walker complex (7/8), cataracts (6/6), and Wilms' tumor (7/8); premature chromatid separation (PCS) was observed in 8/8 propositi and 7/7 carrier parents. Patients without BUB1B mutations were mildly affected with no evidence of cancer, Dandy-Walker malformation or cataract, and rarely (1/7) showed PCS. Finally, patients with biallelic BUB1B mutations showed a moderate phenotype. The distinct MVA clinical groups delineated here point to involvement of at least another mitotic spindle checkpoint gene in addition to the BUB1B gene. (c) 2008 Wiley-Liss, Inc.



___
Source: http://www.hubmed.org/display.cgi?uids=18548531
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Direct uterine sampling with the Tao brush sampler using a liquid-based preparation method for the detection of endometrial cancer and atypical hyperplasia: a feasibility study.



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 13, 2008 at 11:19 PM
Subject: Direct uterine sampling with the Tao brush sampler using a liquid-based preparation method for the detection of endometrial cancer and atypical hyperplasia: a feasibility study.
To: mesothelioma77@gmail.com


[1]Cancer. 2008 Jun 11;
Kipp BR, Medeiros F, Campion MB, Distad TJ, Peterson LM, Keeney GL, Halling KC, Clayton AC

BACKGROUND.: Endometrial cytology sampling devices for direct uterine sampling have been shown in previous studies to be a reliable and relatively painless method for detecting endometrial lesions. The purpose of the current study was to determine the performance characteristics of endometrial cytology for the detection of malignancy and atypical hyperplasia using liquid-based cytology specimens collected with the Tao brush sampler. METHODS.: Brushings of the endometrial cavity were obtained from 139 hysterectomy specimens before routine histopathologic evaluation. Cytology specimens were fixed in PreservCyt and processed using ThinPrep technology. Cytology diagnoses were classified as nondiagnostic, negative, atypical, or positive for malignancy. Histopathologic findings were used as the gold standard for determining the performance characteristics of cytology. RESULTS.: Histopathologic results from the 139 patients included 81 (58%) endometrial cancers, 7 (5%) complex hyperplasias with atypia, 2 (1%) complex hyperplasias without atypia, and 49 (35%) patients with benign histology. The number of specimens diagnosed cytologically as positive, atypical, negative, or nondiagnostic was 60 (43%), 40 (29%), 37 (27%), and 2 (1%) specimens, respectively. The overall sensitivity and specificity of cytology for detecting endometrial cancer and atypical hyperplasia were 95% and 66% when atypical cytology specimens were considered positive. CONCLUSIONS.: The results of the current study indicate that direct endometrial sampling by liquid-based endometrial cytology collected with the Tao brush sampler produces specimens that contain cellular material that may be identified as endometrial cancer or atypical hyperplasia. Both atypical and positive cytology diagnoses are indicators for triage to more specific methods of diagnosis. Cancer (Cancer Cytopathol) 2008. (c) 2008 American Cancer Society.



___
Source: http://www.hubmed.org/display.cgi?uids=18548528
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: The molecular genetics of medulloblastoma: an assessment of new therapeutic targets.



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 13, 2008 at 11:19 PM
Subject: The molecular genetics of medulloblastoma: an assessment of new therapeutic targets.
To: mesothelioma77@gmail.com


[1]Neurosurg Rev. 2008 Jun 12;
Carlotti Jr CG, Smith C, Rutka JT

Medulloblastoma is the most common pediatric primary malignant intracranial neoplasm. The 5-year survival rates vary from 40% to 70% depending on clinical prognostic criteria, and many of the patients who survive exhibit long-term neurocognitive and/or neuroendocrine sequelae. Because of these results, research is required to increase our understanding of the basic biology of medulloblastoma, helping to refine patient stratification, decrease side effects of treatments, identify novel prognostic markers, and discover new less toxic therapies. The recognition that some medulloblastomas occur in familial cancer syndromes has led to some important discoveries in the molecular pathogenesis of medulloblastoma. These syndromes provide us with clues regarding alterations in key signaling or growth factor activation pathways that contribute to medulloblastoma formation. A better understanding of the molecular pathways involved in medulloblastoma formation may allow the discovery of new drugs that act on specific targets, yet many steps must still be taken before clinical use of new drugs. In addition, the identification of a novel signaling pathways in medulloblastoma is often accompanied by the quest for novel pharmacotherapeutics that have the potential to act favorably on this disease.



___
Source: http://www.hubmed.org/display.cgi?uids=18548301
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Anastrozole : a review of its use in postmenopausal women with early-stage breast cancer.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 13, 2008 at 11:19 PM
Subject: Anastrozole : a review of its use in postmenopausal women with early-stage breast cancer.
To: mesothelioma77@gmail.com


[1]Drugs. 2008; 68(9): 1319-40
Sanford M, Plosker GL

Anastrozole (Arimidex((R))) is an aromatase inhibitor approved in the EU, the US and in other countries worldwide for use as an adjuvant treatment in postmenopausal women with early-stage, hormone receptor-positive breast cancer. It is also approved in the EU and other countries worldwide for continuing adjuvant treatment in women who have already had 2-3 years of adjuvant tamoxifen treatment for breast cancer.Anastrozole is an effective primary adjuvant treatment for postmenopausal women with early-stage breast cancer. In patients with hormone receptor-positive tumours, 5 years of anastrozole treatment was more efficacious in reducing breast cancer recurrence than 5 years of tamoxifen, both in a head-to-head comparison and in switching trials when given after 2-3 years of tamoxifen treatment. The treatment benefits have now been shown to extend to 100 months following breast surgery. To date, overall survival was better in anastrozole than tamoxifen recipients in one switching trial and in a meta-analysis of three switching trials. There was no increased benefit in health-related quality of life with anastrozole over tamoxifen. In women who had received 5 years of tamoxifen treatment, continuation of treatment with anastrozole further reduced the risk of breast cancer recurrence. Ongoing head-to-head trials against other third-generation aromatase inhibitors will provide data as to its relative efficacy against these agents. Anastrozole is a generally well tolerated treatment for early-stage breast cancer. Like other aromatase inhibitors, its most important adverse effect was an increased risk of bone fractures, which for anastrozole was restricted to the treatment period. It is still unclear whether primary adjuvant treatment extended beyond 5 years is of benefit and whether primary adjuvant treatment with anastrozole for 5 years is preferable to switching to anastrozole after 2-3 years of tamoxifen treatment. However, the evidence to date establishes anastrozole as a valuable adjuvant and extended adjuvant treatment for postmenopausal women with hormone receptor-positive, early-stage breast cancer.



___
Source: http://www.hubmed.org/display.cgi?uids=18547136
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: [New surgical options for patients with secondary lymphedema of the arm who no longer benefit from regular treatment]



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 13, 2008 at 11:19 PM
Subject: [New surgical options for patients with secondary lymphedema of the arm who no longer benefit from regular treatment]
To: mesothelioma77@gmail.com


[1]Ned Tijdschr Geneeskd. 2008 May 3; 152(18): 1061-5
Voesten HG, Damstra RJ, Klinkert P

Three patients are described who developed irreversible lymphedema of the arm following mastectomy because of breast cancer. Despite maximal conservative treatment, a difference in volume between the affected arm and the healthy arm remained (900-1500 ml). The patients underwent reductive surgery by means of circumferential suction assisted lipectomy, involving removal of hypertrophied adipose tissue. This was the first experience with this procedure in the Netherlands. The differences in arm volume were neutralised completely with a significant improvement of the shoulder function. In order to make the results lasting, the patients have to wear medical elastic stockings day and night for the rest of their lives. Long-term volume measurements are essential.



___
Source: http://www.hubmed.org/display.cgi?uids=18547030
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Overweight, obesity and breast cancer prognosis: optimal body size indicator cut-points.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 13, 2008 at 11:19 PM
Subject: Overweight, obesity and breast cancer prognosis: optimal body size indicator cut-points.
To: mesothelioma77@gmail.com


[1]Breast Cancer Res Treat. 2008 Jun 12;
Majed B, Moreau T, Asselain B,

Background Evidence from the data provided in numerous published articles indicates that obesity and overweight can have a negative prognosis role in breast cancer. However, different Body Size Indicators (BSI) and cut-points have been employed and may partly explain discrepancies between the findings of various studies. Material and methods 14,709 women were recruited, treated and followed for a first unilateral breast cancer. After randomly splitting the patients' data into two groups, a maximum statistical outcome approach was used to select optimal BSI cut-points from a "training sample", when prognosis events were investigated. External validation was then carried out using a "validation sample", and agreement between the selected optimal BSI cut-points was assessed. Body Mass Index (BMI), weight (W), Ideal Weight Ratio (IWR) and Body Surface Area (BSA) were used, and were assessed at the time of diagnosis. Results The selected optimal BSI cut-points were reliable when overall survival, metastasis recurrence and disease free interval events were investigated. The chosen BMI cut-point values matched the overweight cut-point value given by the World Health Organization. Agreement between defined binary BSI was acceptable; however, it varied from "fair" to "very good". Analysis of second primary cancer occurrence and contralateral recurrence events was not conclusive. When local and node recurrence events were taken into account, the results were inconsistent and were linked to an unconfirmed relationship between stoutness and these prognosis events. Conclusions Efficient, optimal BSI cut-points indicate a poorer prognosis, illustrated by a shortened overall survival and an increase of metastasis recurrences, from a BMI value of 25 kg/m(2), a W value of 60 kg, an IWR value of 20% and a BSA value of 1.7 m(2). Further BSI cut-point investigations are needed, taking into account contralateral recurrence and second primary cancer events.



___
Source: http://www.hubmed.org/display.cgi?uids=18546073
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc